UBS Group’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,346
| Closed | -$12K | – | 8774 |
|
|
2019
Q4 | $12K | Sell |
1,346
-2,043
| -60% | -$24.8K | ﹤0.01% | 7216 |
|
|
2019
Q3 | $57K | Buy |
3,389
+1,287
| +61% | +$19.2K | ﹤0.01% | 6135 |
|
|
2019
Q2 | $28K | Sell |
2,102
-2,040
| -49% | -$30.6K | ﹤0.01% | 6399 |
|
|
2019
Q1 | $55K | Buy |
4,142
+869
| +27% | +$12.6K | ﹤0.01% | 5480 |
|
|
2018
Q4 | $72K | Buy |
+3,273
| New | +$60.2K | ﹤0.01% | 5819 |
|
|
2018
Q3 | – | Sell |
-260
| Closed | -$5K | – | 8452 |
|
|
2018
Q2 | $5K | Sell |
260
-1,397
| -84% | -$28.1K | ﹤0.01% | 7504 |
|
|
2018
Q1 | $35K | Buy |
1,657
+493
| +42% | +$9.66K | ﹤0.01% | 5988 |
|
|
2017
Q4 | $27K | Sell |
1,164
-787
| -40% | -$18.3K | ﹤0.01% | 6338 |
|
|
2017
Q3 | $41K | Buy |
1,951
+1,831
| +1,526% | +$43.9K | ﹤0.01% | 5943 |
|
|
2017
Q2 | $3K | Sell |
120
-387
| -76% | -$12.5K | ﹤0.01% | 7327 |
|
|
2017
Q1 | $17K | Buy |
+507
| New | +$18.7K | ﹤0.01% | 6285 |
|
|
2016
Q3 | – | Sell |
-505
| Closed | -$33K | – | 8094 |
|
|
2016
Q2 | $33K | Buy |
+505
| New | +$31.1K | ﹤0.01% | 5869 |
|
Other funds holding ZBIO
UBS Group's ZBIO Position: Q1 2020 in Review
UBS Group sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q1 2020, closing a stake of 1,346 shares — an estimated $12K sold.
UBS Group first reported a position in ZBIO in Q2 2016 and held it in 12 quarters. The position peaked at $72K in Q4 2018. 1 fund tracked by Wall St. Rank holds ZBIO as of Q1 2020.
- UBS Group reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
- UBS Group sold 1,346 ProShares UltraPro Short NASDAQ Biotechnology shares in Q1 2020, an estimated $12K.
- UBS Group first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q2 2016 and held it in 12 quarters.
- UBS Group's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $72K in Q4 2018.
- 1 fund tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q1 2020.
Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.